跳至主要内容
临床试验/EUCTR2012-000179-17-DE
EUCTR2012-000179-17-DE进行中(未招募)不适用

Effect of Linagliptin in comparison with Glimepiride as add on to Metformin on postprandial beta cell function, postprandial metabolism and oxidative stress in patients with type 2 diabetes mellitus

ikfe GmbH0 个研究点开始时间: 2012年2月22日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Diabetes mellitus type 2
  • 2.HbA1c = 6.5% - = 8.5%
  • 3.HbA1c = 7.0% - = 8.5% for those patients with a significant cardiovascular history
  • 4.Treatment with metformin at a maximum tolerated dose
  • 5.Age 45 – 75 years (inclusively)
  • 6.Patient consents that his/her family physician/diabetologist will be informed of trial participation.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 40

排除标准

  • 11.Pretreatment with PPAR gamma agonists within the last three months
  • 2.History of type 1 diabetes
  • 3.Uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg)
  • 4.Acute infections
  • 5.Medical history of hypersensitivity to the study drugs or to drugs with similar chemical structures
  • 6.History of severe or multiple allergies
  • 7.Treatment with any other investigational drug within 3 months before trial entry.
  • 8.Progressive fatal disease
  • 9.History of drug or alcohol abuse in the past 2 years
  • 10.State after kidney transplantation
  • 11.Serum potassium > 5.5 mmol/L
  • 12.Pregnancy or breast feeding
  • 13.Sexually active woman of childbearing age not practicing a highly effective method of birth control as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomized partner.
  • 14.Acute myocardial infarction, open heart surgery or cerebral event (stroke/TIA) within the previous 30 days
  • 15.Any elective surgery during study participation
  • 16.Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit
  • 17.History of pancreatitis
  • 18.History of dehydration, pre-coma diabeticum or diabetic ketoacidosis
  • 19.Acute or scheduled investigation with iodine containing radiopaque material
  • 20.Uncontrolled unstable angina pectoris
  • 21.History of pericarditis, myocarditis, endocarditis
  • 22.Recent pulmonary embolism
  • 23.Hemodynamic relevant aortic stenosis
  • 24.Aortic aneurysm
  • 25.Regular use of NSAID’s (no acute use of NSAID within 48 hours before V2,V4,V5)
  • 26.Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study
  • 27.History of respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (Creatinine > 1.1 mg/dl in women and > 1.5 mg/dl in men ), neurological, psychiatric and/or hematological disease as judged by the investigator
  • 28.Lactose intolerance
  • 29.Intake of Coumarin or coumarin derived compounds such as phenprocoumon (Marcumar) or warfarin (Coumadin, Warfant)

研究者

发起方
ikfe GmbH

相似试验